A biomimetic infrared biochip for enhancing cell activity and its application and use method

Abstract

The present invention belongs to the field of biochips, and specifically relates to a biomimetic infrared biochip for enhancing cell activity, comprising a shell and a chip body encapsulated in the shell; the chip body comprises an inductive transceiver and a resonant crystal, the inductive transceiver is electrically connected to the resonant crystal; the inductive transceiver is used to receive biowaves emitted by an organism and / or the environment to the resonant crystal, the resonant crystal is used to receive the biowaves transmitted from the inductive transceiver, resonate and amplify the received biowaves to form infrared resonant waves with a wavelength of 9.12μm to 9.56μm, and transmit the infrared resonant waves to the inductive transceiver, the inductive transceiver receives the infrared resonant waves transmitted from the resonant crystal, and emits the infrared resonant waves; the infrared resonant waves are forward and reverse direction waves, and the forward and reverse switching frequency of the forward and reverse direction waves is 30MHz to 300MHz. When the biochip is worn on the organism, it can emit infrared resonant waves of specific wavelengths to achieve a therapeutic effect.

Description

Technical Field

[0001] The present invention belongs to the technical field of biochips, and in particular relates to a biomimetic infrared biochip for enhancing cell activity and an application and use method thereof. Background Art

[0002] Chronic diseases, also known as chronic non-communicable diseases, are a general term for diseases that are not contagious and accumulate over a long period of time to form disease-like damage. Common chronic diseases include cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, diabetes, oral diseases, and endocrine, kidney, bone, and nerve diseases. The harm of chronic diseases mainly causes damage to important organs such as the brain, heart, and kidneys, which can easily cause disability, affect labor capacity and quality of life, and the medical expenses are extremely expensive. A survey by the World Health Organization shows that 60% of the causes of chronic diseases depend on personal lifestyles, and are also related to factors such as genetics, medical conditions, social conditions, and climate. With the continuous acceleration of my country's industrialization, urbanization, and population aging, the impact of residents' lifestyles, ecological environment, and food safety on health has gradually emerged, the number of chronic disease incidence, illness, and death has continued to increase, and the burden of chronic diseases on the masses has become increasingly heavy. According to the goal of the "Medium- and Long-Term Plan for the Prevention and Treatment of Chronic Diseases in China (2017-2025)", by 2025, the risk factors of chronic diseases will be effectively controlled, and life cycle health management will be achieved for the entire population. We will strive to reduce the premature mortality rate of people aged 30 to 70 due to cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases and diabetes by 20% compared with 2015, gradually increase the healthy life expectancy of residents, and effectively control the burden of chronic diseases. The root cause of chronic diseases is the decline of tissue and organ functions. Therefore, the focus of treating chronic diseases is to restore tissue and organ functions. As the risk factors of adverse drug reactions increase, the difficulties in treating chronic diseases also increase. Some non-drug therapies have gradually become popular and used for the rehabilitation treatment of chronic diseases. However, there are also shortcomings such as painful treatment process, unclear efficacy, and high cost.

[0003] Among non-drug therapies, far-infrared therapy is a new technology with great development potential. It has the advantages of wide indications, good efficacy, quick results, low cost, simple method, no damage, no pain, and few side effects. It has developed rapidly in my country. Objects in nature always absorb energy radiated by other objects, and objects with a temperature higher than absolute zero (-273℃) will radiate part of the energy at a certain wavelength, commonly known as thermal radiation. When an object absorbs energy, electron vibration will occur, causing the electron to jump to a higher energy level and leave the original orbit. In the process from high energy level to low energy level, energy will be released, which is called radiation energy. The radiation energy is output in the form of infrared rays. Therefore, all objects above absolute zero emit infrared rays to varying degrees. Far infrared rays are a kind of electromagnetic wave, a radiation with strong thermal effect. Its wavelength that is beneficial to the human body is 2~22µm. Sunbathing is in this band range of sunlight. People also call the far infrared rays of 2~22µm "the line of life". Far infrared rays have strong penetration and radiation power, significant temperature control effect and resonance effect, and are easily absorbed by objects and converted into internal energy of objects. After being absorbed by the human body, far infrared rays not only produce thermal effects on the surface of the skin, but also cause the vibration of water molecules in the body. Then, through resonance absorption, the far infrared electro-optical energy that penetrates the human skin is converted into thermal energy, which promotes the temperature rise of deep subcutaneous tissue. This effect can stimulate cell activity, cause capillary expansion, accelerate blood flow, increase microcirculation blood flow, strengthen metabolism between tissues, increase tissue regeneration ability, improve the body's immune ability, fundamentally eliminate diseases, and play a series of medical and health care effects. In general, the mechanism of treatment mainly relies on the "thermal effect" caused by infrared rays. At present, the commonly used materials and products that generate far infrared rays include: biochar, carbon fiber products, tourmaline, far infrared ceramics and products, (non) metal oxides and silicon carbide, graphene, etc. The more mature and widespread technologies in existing known technologies and product applications are applied to products in different fields. However, they have shortcomings such as the wide wavelength bandwidth of far-infrared rays, the inability to effectively concentrate energy, or being limited by the far-infrared emissivity of raw materials. Therefore, the effect of improving human health is also limited. Summary of the invention

[0004] The purpose of the present invention is to provide a bionic infrared biochip for enhancing cell activity. When the biochip is worn on a biological body, it can emit infrared resonance waves of a specific wavelength and a forward and reverse switching frequency to the biological body to effectively improve health effects.

[0005] The above-mentioned purpose is achieved by the following technical solutions.

[0006] The first aspect of the present invention provides a biomimetic infrared biochip for enhancing cell activity, the biochip comprising a shell and a chip body encapsulated in the shell;

[0007] The chip body comprises an inductive transceiver and a resonant crystal, wherein the inductive transceiver is electrically connected to the resonant crystal;

[0008] The inductive transceiver is used to receive the bio-waves emitted by the organism and / or the environment to the resonant crystal, the resonant crystal is used to receive the bio-waves transmitted from the inductive transceiver, resonate and amplify the received bio-waves to form infrared resonant waves with a wavelength of 9.12µm~9.56µm, and transmit the infrared resonant waves to the inductive transceiver, the inductive transceiver receives the infrared resonant waves transmitted from the resonant crystal, and emits the infrared resonant waves;

[0009] The infrared resonance wave is a forward and reverse direction wave, and the forward and reverse switching frequency of the forward and reverse direction waves is 30MHz~300MHz.

[0010] In some embodiments, the wavelength of the infrared resonance wave is 9.22µm~9.46µm.

[0011] In some embodiments, the wavelength of the infrared resonance wave is 9.322µm~9.358µm.

[0012] In some embodiments, the forward and reverse switching frequency of the forward and reverse direction waves is 100 MHz to 200 MHz.

[0013] In some embodiments, the forward and reverse switching frequency of the forward and reverse direction waves is 120MHz~180MHz.

[0014] In some embodiments, the forward and reverse switching frequency of the forward and reverse direction waves is 120MHz~130MHz.

[0015] In some embodiments, the infrared resonance wave is a sine wave, a sawtooth wave or a square wave.

[0016] In some embodiments, a plurality of chip bodies are provided, and each chip body array is arranged in the housing.

[0017] A second aspect of the present invention provides a use of the biochip as described above in enhancing the activity of biological cells.

[0018] The third aspect of the present invention provides a method for using a biochip for enhancing cell activity, based on the biochip as described above, comprising the following steps:

[0019] Wearing or attaching the biochip on a living body, with the biochip being 0 to 30 cm away from the skin of the living body;

[0020] The inductive transceiver receives the bio-waves emitted by the organism and / or the environment to the resonant crystal;

[0021] The resonant crystal receives the bio-wave transmitted from the inductive transceiver, and forms an infrared resonant wave with a wavelength of 9.12µm~9.56µm after resonant amplification of the received bio-wave, and the infrared resonant wave is a forward and reverse direction wave, and the forward and reverse switching frequency of the forward and reverse direction wave is 30MHz~300MHz, and transmits the infrared resonant wave to the inductive transceiver;

[0022] The inductive transceiver receives the infrared resonance wave transmitted from the resonance crystal, and emits the infrared resonance wave to the biological body.

[0023] In the present invention, a biochip emits infrared resonance waves of a specific wavelength (9.12µm~9.56µm, most preferably 9.322µm~9.358µm), and the infrared resonance waves emitted by the biochip are coordinated to form forward and reverse direction waves at a specific forward and reverse switching frequency (30MHz~300MHz), wherein the infrared resonance waves of the specific wavelength can be well absorbed by the organism, promoting the effects of blood flow and flow velocity, as well as enhancing mobility and improving mitochondrial NAD+ / NADH efficiency; it is found that this type of biochip also has a good therapeutic effect on sensorineural hearing loss or tinnitus, and it is also found that this type of biochip is helpful in restoring blood flow to the brain after a stroke, and significantly improves mobility after a stroke, and has good clinical use value and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a physical picture of the biochip (code AL-0) used in Example 1.

[0025] Figure 2 This is a physical picture of another chip FAKE used in Example 1.

[0026] Figure 3 (A) is the moving path result diagram of rat movement trajectory recording and analysis; Figure 3 (B) is the result of rat brain blood flow.

[0027] Figure 4 A-B are the results of rat brain blood flow within 1d-3d after chip treatment.

[0028] Figure 5 Figures ac are the results of rat brain blood flow within 0-24 hours after chip treatment.

[0029] Figure 6 This is a graph showing the effect of the biochip on the NAD+ / NADH efficiency of cell mitochondrial activity.

[0030] Figure 7It is a schematic diagram of the internal structure of a biochip for enhancing cell activity according to an embodiment of the present invention.

[0031] Description of reference numerals:

[0032] 100. Biochip;

[0033] 1. Shell; 2. Chip body; 21. Inductive transceiver; 22. Resonant crystal. DETAILED DESCRIPTION

[0034] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0035] The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.

[0036] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.

[0037] The present invention provides a biochip 100 for enhancing cell activity, such as Figure 7 As shown, the biochip 100 includes a shell 1 and a chip body 2 encapsulated in the shell 1 .

[0038] The chip body 2 includes an inductive transceiver 21 and a resonant crystal 22 , and the inductive transceiver 21 is electrically connected to the resonant crystal 22 ; the inductive transceiver 21 is used to receive biological waves emitted by a biological body and / or the environment to the resonant crystal 22 .

[0039] The resonant crystal 22 is used to receive the bio-wave transmitted from the inductive transceiver 21, resonate and amplify the received bio-wave to form an infrared resonant wave with a wavelength of 9.12µm~9.56µm, and transmit the infrared resonant wave to the inductive transceiver 21. The inductive transceiver 21 receives the infrared resonant wave transmitted from the resonant crystal 22 and emits the infrared resonant wave;

[0040] The infrared resonance wave is a forward and reverse direction wave, and the forward and reverse switching frequency of the forward and reverse direction waves is 30MHz~300MHz.

[0041] The sources of the bio-waves of the resonance crystal 22 include: first, the bio-waves of the human body, specifically from the thermal effect of the human body, ATP of the citric acid cycle of cells, and nerve pulses. Second, the short-wave radiation in the earth's space. These two energy wave sources are absorbed by the inductive transceiver 21 of the biochip 100 into the resonance crystal 22 for resonance. After the resonance, the energy wave has a larger amplitude and stronger energy, and then it is supplied back to the human body through the inductive transceiver 21.

[0042] Specifically, when the biochip 100 is worn or attached to a biological body, the working principle of the biochip 100 is as follows:

[0043] The inductive transceiver 21 receives the biological waves emitted by the organism and / or the environment to the resonant crystal 22;

[0044] The resonant crystal 22 receives the bio-wave transmitted from the inductive transceiver 21, and resonates and amplifies the received bio-wave to form an infrared resonant wave with a wavelength of 9.12µm to 9.56µm, and transmits the infrared resonant wave to the inductive transceiver 21;

[0045] The inductive transceiver 21 receives the infrared resonance wave transmitted from the resonance crystal 22, and emits the infrared resonance wave to the biological body.

[0046] In the present invention, the infrared resonance wave of a specific wavelength (9.12µm~9.56µm, preferably 9.322µm~9.358µm) is emitted by the biochip 100, and the infrared resonance wave emitted by the biochip 100 is switched at a specific forward and reverse switching frequency (30MHz~300MHz) to form a forward and reverse direction wave, wherein the infrared resonance wave of the specific wavelength can be well absorbed by the organism, promote the effect of blood flow and flow velocity, enhance mobility, improve mitochondrial NAD+ / NADH efficiency, have a significant effect of inhibiting inflammation, and also have a good therapeutic effect on sensorineural hearing loss or tinnitus, and have good clinical use value and social benefits.

[0047] Preferably, the wavelength of the infrared resonance wave is 9.22µm~9.46µm. Further preferably, the wavelength of the infrared resonance wave is 9.322µm~9.358µm. The infrared resonance wave fluctuates according to the normal body temperature of the human body. Since the normal body temperature of the human body usually fluctuates between 36.5-37.7°C, the matching infrared resonance wave wavelength is 9.322~9.358μm, that is, the minimum wavelength is 9.322μm, the maximum wavelength is 9.358μm, and it is a sine wave, a sawtooth wave or a square wave.

[0048] Specifically, the resonant crystal 22 may be of a conventional structure. For ease of understanding, the structure and working principle of the resonant crystal 22 are briefly described here: the resonant crystal 22 includes a substrate, a crystal oscillator circuit, and a packaging shell. The packaging shell and the substrate cooperate to form a packaging cavity, the crystal oscillator circuit is located in the packaging cavity, the crystal oscillator circuit includes a crystal resonator and a crystal oscillator chip, the crystal resonator includes a crystal sheet and an electrode, and the crystal oscillator chip includes an amplifier, a feedback circuit, and an output circuit.

[0049] The crystal piece is a quartz crystal piece, which is made into a specific shape and size by photolithography; the electrode is made of metal film, and the crystal piece and the electrode are welded by laser or electron beam. The crystal resonator uses the electromechanical coupling effect of the crystal piece to generate resonance under the action of mechanical oscillation and electric field.

[0050] Specifically, when the frequency of the applied voltage is equal to the specific oscillation frequency of the crystal piece, the crystal piece will generate mechanical vibrations, causing the crystal piece to fluctuate under the action of mechanical and electric fields, and transmit the fluctuations to the electrodes of the crystal piece. Since the crystal piece has precise oscillation frequency characteristics, the resonant frequency of the crystal piece is very stable.

[0051] The biological wave is amplified by the resonance generated by the crystal oscillator, and the amplified resonant wave is transmitted to the inductive transceiver 21. The starting time and starting energy of the crystal oscillator determine the energy efficiency of the wireless system where the crystal oscillator is located. Injecting energy into the crystal oscillator can quickly increase the equivalent dynamic current of the crystal oscillator, thereby reducing the starting time and energy consumption. However, the premise of energy injection is that the injection frequency is consistent with the crystal oscillator resonant frequency. The frequencies required by the crystal oscillator in the selection process are mostly marked on the surface of the crystal oscillator. Common ones are 32.768KHz, 4MHZ, 12.288MHZ, 40MHZ and 64MHZ, etc. Crystal oscillators with frequencies below 10MHZ are usually regarded as low frequencies, and crystal oscillators above 10MHZ are regarded as high frequencies. The crystal oscillator selected by the present invention is an ultra-high frequency with a frequency of 30MHz~300MHz. The amplifier is an important component of the crystal oscillator chip. The amplifier amplifies the weak signal output by the crystal resonator. The amplified signal is fed back to the crystal resonator through the feedback circuit, so that the oscillator can oscillate continuously to maintain the stability of the crystal resonator. The output circuit outputs the signal generated by the crystal resonator to the inductive transceiver 21 to be transmitted to the human body; the output circuit outputs a stable high-frequency positive and negative wave oscillation signal.

[0052] In some embodiments, the inductive transceiver 21 may include a receiving antenna and a transmitting antenna, or the receiving antenna and the transmitting antenna may be integrated together. Specifically, uplink and downlink signals may be distinguished through a specific duplex design, thereby achieving transmission and reception at the same frequency.

[0053] In some embodiments, the forward and reverse switching frequency of the forward and reverse direction waves is 100 MHz to 200 MHz.

[0054] In some embodiments, the forward and reverse switching frequency of the forward and reverse direction waves is 120 MHz to 180 MHz.

[0055] In some embodiments, the infrared resonance wave is a sine wave, a sawtooth wave or a square wave.

[0056] In some embodiments, the chip bodies 2 are provided in plurality, and the chip bodies 2 are arranged in an array in the housing 1. Specifically, 5 to 120 chip bodies 2, preferably 30 to 90 chip bodies 2, may be arranged around relevant acupuncture points and lesions in a symmetrical distribution.

[0057] In some embodiments, the thickest part of each formed biochip 100 does not exceed 1 mm, and the main layout of the sensing transceiver 21 is a printed circuit board. The biochip 100 can be worn or attached to a biological body by attaching it to different carriers, wherein the biochip 100 can be provided with at least one as needed, and there is no special limitation here.

[0058] The present invention also provides a use of the biochip 100 as described above in enhancing the activity of biological cells.

[0059] The biochip 100 is combined with the meridian acupoints of the human body and can be applied to cabins for stroke sequelae, helmets for cranial nerve loss, blood pressure bracelets, cushions for reproductive inflammation, pillows for sleep problems, glasses for visual fatigue, underwear pads for breast hyperplasia, wigs and other common chronic disease scenarios.

[0060] The present invention also provides a method for using the biochip 100 for enhancing cell activity, based on the biochip 100 as described above, comprising the following steps:

[0061] The biochip 100 is worn or attached to a biological body, and the biochip 100 is 0 to 30 cm away from the biological body's skin; specifically, the biochip 100 can be attached to different carriers by adjusting the shape and volume of the biochip 100 so as to be used on any wearable or wearable object. The shape of the carrier is preferably but not limited to round or square, and the carrier material is made of silica gel, plastic sealing material, and waterproof oil paper. The area size can be adjusted arbitrarily according to the usage scenario, and at the same time, the inductive transceiver 21 and the resonant crystal 22 are reduced or enlarged in the same proportion, or the length and coverage area of ​​the inductive transceiver are increased or decreased to match the adjustment of the carrier size.

[0062] The inductive transceiver 21 receives the biological waves emitted by the organism and / or the environment to the resonant crystal 22;

[0063] The resonant crystal 22 receives the bio-wave transmitted from the inductive transceiver 21, and forms an infrared resonant wave with a wavelength of 9.12µm~9.56µm after resonant amplification of the received bio-wave, and the infrared resonant wave is a forward and reverse direction wave, and the forward and reverse switching frequency of the forward and reverse direction wave is 30MHz~300MHz, and transmits the infrared resonant wave to the inductive transceiver 21;

[0064] The inductive transceiver 21 receives the infrared resonance wave transmitted from the resonance crystal 22 and emits the infrared resonance wave to the biological body.

[0065] The following are specific embodiments.

[0066] Example 1 Effect of biochip on the mobility and cerebral blood flow in rat stroke model

[0067] 1. Chip structure

[0068] The biochip 100 (codenamed AL-0) of this embodiment is as follows Figure 1 As shown, it includes a shell 1 and a chip body 2 encapsulated in the shell 1; the chip body 2 includes an inductive transceiver 21 and a resonant crystal 22, and the inductive transceiver 21 is electrically connected to the resonant crystal 22; the inductive transceiver 21 is used to receive the biological waves emitted by the organism and the environment to the resonant crystal 22, and the resonant crystal 22 is used to receive the biological waves transmitted from the inductive transceiver 21, resonate and amplify the received biological waves to form infrared resonant waves with a wavelength of 9.322µm~9.358µm, and transmit the infrared resonant waves to the inductive transceiver 21, and the inductive transceiver 21 receives the infrared resonant waves transmitted from the resonant crystal 22 and emits the infrared resonant waves. Wherein, the infrared resonant wave is a sine wave, and the forward and reverse switching frequency of the sine wave is 120MHz.

[0069] Other chips: FAKE (code name), such as Figure 2 shown.

[0070] 2. Experimental design

[0071] The rats were divided into three groups, two experimental groups and one control group, with three rats in each group (SD rats). The experimental group one (AL-0) and the experimental group two (FAKE) were induced to have embolic stroke model by MCAO suture plugging. Then, the biochip liner was attached to the outside of the bottom of the cage of the experimental group one (AL-0) and the other chip liner was attached to the outside of the bottom of the cage of the experimental group two (FAKE).

[0072] All of the above are fifty-core chip cores, but from different sources. The biochip of the experimental group (code-named AL-0) is provided by Tianlineng Company, and the biochip FAKE chip of the control group comes from Shenzhen Yikatong IoT Technology Co., Ltd.

[0073] Feed, water and ventilation are provided daily, and the temperature is controlled at 22 degrees Celsius and the relative humidity is 70%.

[0074] The experiment lasted for twenty days. After the experiment, all rats were killed and their brain tissues were extracted for analysis.

[0075] After the experiment, Doppler radar imaging was used to observe the cerebral blood flow status of the three groups of SD rats.

[0076] The moving paths analyzed by biological motion trajectory recording are as follows Figure 3 As shown in (A), it can be found that the activity of rats in the first AL-0 treatment group was significantly improved, while the rats in the second FAKE treatment group recovered a small amount of activity but had no significant improvement. The results of brain blood flow analysis were as follows Figure 3 As shown in (B), the brain blood flow of rats in the AL-0 group was significantly greater than that in the FAKE group.

[0077] like Figure 4 A and Figure 4 As shown in B, the cerebral blood flow of rats in the AL-0 treatment group I was significantly improved on the third day of the experiment, while the blood flow of rats in the FAKE treatment group II was only slightly restored.

[0078] like Figure 5 As shown in a to c, the cerebral ischemia of the rats in the AL-0 first treatment group and the rats in the second treatment group was observed to be rapid and severe within fifty minutes after the MCAO treatment.

[0079] The rats in the first AL-0 treatment group and the rats in the second FAKE treatment group were treated with AL-0 and FAKE respectively. At different time points within 24 hours, it was seen that the blood flow in their brains gradually recovered, and the blood flow in the AL-0 treatment group was much greater than that in the FAKE treatment group.

[0080] From the above, we can see that after comparing the movement ability and brain blood flow efficiency analysis of rat stroke model, the effect of other chips FAKE is obviously inferior to the AL-O biochip.

[0081] Example 2 Effect of biochip on the efficiency of NAD+ / NADH in cell mitochondrial activity

[0082] Comparison of the biochip (AL-0) of Example 1 and other chips (FAKE) in the analysis of the NAD+ / NADH efficiency of cell mitochondrial activity

[0083] The in vitro cell culture model of human gingival epithelial cells (HGECs) was used to observe the cell activity under the intervention of the biochip liner (codenamed AL-0) and other chip liners (codenamed: FAKE). The NAD+ / NADH kit-WST was used to test the cell activity, and the benefits of the two chips on cell mitochondrial activity were observed.

[0084] like Figure 6 As shown, in the in vitro cell culture mode, the total NAD+ / NADH ratio of the TREAMENT GROUP treated with the AL-0 biochip was close to 3.8, while the activation degree of the NAD+ / NADH ratio of the cell mitochondrial activation indicator in the FAKE treatment group was significantly lower.

[0085] From the above, we can see that the results of the in vitro cell culture model observation of human gingival epithelial cells (HGECs) show that the FAKE other chips do not help improve the mitochondrial activity of biological cells, which is far less than the AL-0 biochip.

[0086] Example 3 Study on the biochip treatment of sensorineural hearing loss

[0087] 1. Introduction

[0088] This example is a comparative study on the treatment of sensorineural hearing loss (SNHL) with bio-energy core moxibustion tablets and biochips. Patients with SNHL diagnosed by pure tone audiometry, otolaryngology, and traditional Chinese medicine physicians were randomly divided into two groups, a core moxibustion group and a control group. The control group used medication to treat SNHL, and the core moxibustion group wore bio-energy core moxibustion tablets and biochip-specific acupoint headgear, 1 tablet / each acupoint, on the basis of medication treatment to treat SNHL. Subjects were allowed to use emergency medications throughout the experiment, but they could not use emergency medications 24 hours before any follow-up observation.

[0089] The main efficacy indicators of this embodiment are:

[0090] 1.3.1 On the 15th day, the average values ​​of the pure tone audiometry test scores of the test subjects at different levels were collected.

[0091] 1.3.2 The average values ​​of the pure tone audiometry test scores of the test subjects at different levels on the 60th day.

[0092] 1.4 Treatment

[0093] After the subjects are qualified in screening and sign the informed consent, the attending physician will treat them according to their condition and give them the medicine within 2 hours after enrollment.

[0094] 2. Subjects

[0095] 2.1 Diagnostic criteria

[0096] 2.1.1 Non-fluctuating sensorineural hearing loss that may occur suddenly within minutes, hours or 3 days.

[0097] Hearing loss of at least 20dB in two consecutive frequencies;

[0098] 2.1.2 Mostly unilateral, occasionally bilateral at the same time or successively; the cause is unknown;

[0099] 2.1.3 Accompanied by tinnitus and ear plugging;

[0100] 2.1.4 Accompanied by dizziness, nausea, and vomiting, but not recurring

[0101] 2.1.5 Except for the auditory nerve, there are no other symptoms of cranial nerve damage.

[0102] 2.2 Inclusion criteria

[0103] 2.2.1 Meet the diagnostic criteria for SNHL;

[0104] 2.2.2 Aged 18-70 years, excluding severe or profound deafness

[0105] 2.2.3 No other serious complications;

[0106] 2.2.4 Informed consent: the patient is able to cooperate with treatment and examination.

[0107] 2.3 Exclusion criteria:

[0108] 2.3.1 Hereditary deafness

[0109] 2.3.2 Non-hereditary congenital deafness

[0110] 2.3.3 Patients with a clear history of trauma-induced deafness

[0111] 2.3.4 Patients with deafness clearly caused by tumors

[0112] 2.3.5 Psychogenic deafness and feigned deafness

[0113] 2.3.6 Cases where treatment was not carried out as prescribed

[0114] 2.3.7 Cases where incomplete data affect the judgment of efficacy.

[0115] 3. Treatment options

[0116] 3.1 Bioenergy core moxibustion tablets and biochips used in the experiment

[0117] Bioenergy core moxibustion tablets and biochips are selected from biochips and bioenergy core moxibustion tablets produced by Guangzhou Tianlineng Technology Co., Ltd.

[0118] 3.2 Treatment

[0119] 3.2.1 Control Group:

[0120] Conventional drug treatment (15 days per course, three courses in total):

[0121] 3.2.1.1 5% glucose injection 250ml + Ginkgo biloba extract 70mg, bid, ivgtt, for 15 consecutive days.

[0122] 3.2.1.2 Add 10ug of alprostadil hydrochloride to 100ml of 0.9% sodium chloride, pour into a pot, bid, and use continuously for 15 days.

[0123] 3.2.1.3 Adenosylcobalamin 1.5 mg qd im for 15 consecutive days.

[0124] The above method is applied for 15 days in each course of treatment, and relevant examinations are performed and recorded.

[0125] 3.2.2 Bioenergy Core Moxibustion Tablets Treatment Group

[0126] On the basis of the treatment plan of the control group, the same biochip (AL-0) and bioenergy core moxibustion tablets as in Example 1 were used together as core moxibustion group 1. The doctor guided the patient to wear the acupoint headgear developed by Guangzhou Tianlineng Technology Co., Ltd. Main acupoints: Baihui, Tinggong, Yifeng, Taiyang, auxiliary acupoints: Waiguan, Fengchi. 1 tablet / each acupoint, and continued to wear for 45 days after stopping the drug. Observe and record the examination results.

[0127] 3.3 Monitoring methods of subject compliance:

[0128] Detected by checking treatment diary.

[0129] 3.4 Other medications and treatments

[0130] 3.4.1 Subjects must stop taking all medications during the wash-out period.

[0131] 3.4.2 If the subject has been taking therapeutic exercise therapy for at least 8 weeks before enrollment, they may continue to do so. Other new exercise therapies, physical therapies, and massage therapies are not allowed.

[0132] 3.4.3 The use of anti-inflammatory drugs for diseases other than SNHL is considered as other medications. If the medication is related to an adverse event, it should be recorded in the medical record report form (CRF).

[0133] 3.4.4 No other trial drugs may be taken during this trial. If the subject needs to take any medication (including prescription and over-the-counter drugs) during the trial, the subject must inform the researcher and obtain consent, which will be recorded in the CRF.

[0134] 3.4.5 Subjects must stop taking all medications except emergency treatment after screening.

[0135] 3.46 The washout period is approximately at least 5 times the half-life of the drug. Any issues that arise during the washout period must be submitted to the medical monitoring team for review. However, if the subject indicates that he or she has not taken any medication, he or she does not need to undergo a washout period.

[0136] 3.4.7 During the trial period, electrical stimulation therapy and acupuncture are not allowed. If used, they must be stopped 7 days before enrollment.

[0137] 3.48 Efficacy Evaluation

[0138] Recovery: The hearing thresholds of each frequency of 0.25-4kHz are restored to normal or healthy ear levels, or to the level before the disease

[0139] Significantly effective: The average hearing ability at the above frequencies improved by more than 30 decibels.

[0140] Effective: Average hearing at the above frequencies is improved by more than 15-30 decibels.

[0141] Ineffective: The average hearing improvement in the above frequencies is less than 15 decibels.

[0142] 3.49 Pure tone audiometry test

[0143] The GSI-16 audiometer was used. The zero level of the audiometer was in accordance with the standard of GB4854-84. The sound was given through TDH-49P headphones and MX-41 / AR ear pads. The pure tone audiometry operation method was carried out in accordance with the provisions of GB78548-87. The entire test was carried out in a double soundproof room with an ambient noise of 16dB.

[0144] 3.50 Reasons for Subject Termination of Trial

[0145] The subjects can withdraw from the trial at any time after taking the core moxibustion tablets. The criteria for the subjects to terminate the trial include but are not limited to the following two points:

[0146] 1) The researcher believes that continuing the trial will endanger the safety of the subjects, including adverse events

[0147] 2) The subjects' compliance with the trial schedule and procedures was poor.

[0148] 4. Results

[0149] 4.1 Patient Baseline

[0150] A total of 60 patients were recruited from November 2017 to June 2018. All patients signed informed consent. The experiment was registered with the hospital ethics committee. The average age of the patients was 50.81±5.70 years. The average time of diagnosis was 1.25±0.24 months. The average course of disease was 5.1±4.06. See Table 4.1

[0151] 4.1 Patient Baseline Values ​​(n=60)

[0152]

[0153] 4.2 Results

[0154] 4.2.1 The hearing changes of patients in group 1 treated with Xinjiu tablets before and after treatment are shown in Table 4.2

[0155] Table 4. Comparison of pure tone audiometry test results before and after treatment in core moxibustion group 1 (-X±S) (dB)

[0156]

[0157] Analysis of Table 4.2 showed that the stimulation of core moxibustion group 1 improved the hearing of patients of all levels of SNHL to varying degrees. The difference between patients with mild and moderate hearing loss after treatment and before treatment was extremely significant (P<0.001), while there was no significant difference between patients with severe hearing loss before and after treatment (P>0.05).

[0158] 4.2.2 Effects of the two treatment methods on the efficacy of the core moxibustion tablets group 1 and the control group are shown in Table 4.3

[0159] Table 4. Comparison of pure tone audiometry test results between 3-core moxibustion tablets group 1 and control group after treatment (-X±S) (dB)

[0160]

[0161]

[0162] Analysis of Table 4.3 showed that the two treatment methods improved the hearing of SNHL patients at different levels to varying degrees. The effect of core moxibustion group 1 on mild deafness was significantly better than that on the control group (P<0.05), and the effect of core moxibustion group 1 on moderate deafness was significantly better than that on the control group (P<0.001). There was no significant difference between core moxibustion group 1 and the control group in severe deafness (P>0.05).

[0163] 4.2.3 Comparison of the efficacy of the core moxibustion group and the control group according to the pure tone audiometry test efficacy evaluation criteria is shown in Table 4.4

[0164] Table 4. Comparison of the therapeutic effects between the 4-core moxibustion group and the control group (%)

[0165]

[0166] Table 4.4 shows that the effective rates of core moxibustion group 1 and control group were 88.3% and 59.0%, respectively. After statistical processing, the difference in efficacy between the two groups was significant (P<0.05), which further shows that the efficacy of core moxibustion group 1 is better than that of the control group in general.

[0167] From the above embodiments, it can be seen that the biochip provided by the present invention emits infrared resonance waves with a wavelength of 9.322µm~9.358µm through the biochip, and the infrared resonance waves emitted by the biochip are formed into positive and negative waves according to a specific positive and negative switching frequency (30MHz~300MHz), wherein the infrared resonance waves of the specific wavelength can be well absorbed by the organism, promote the effect of blood flow and flow rate, enhance mobility, and improve mitochondrial NAD+ / NADH efficiency. We found that this type of biochip also has a good therapeutic effect on sensorineural deafness or tinnitus, and also found that this type of biochip helps the brain gradually restore blood flow after stroke, and significantly improves the mobility after stroke. We analyzed that the possibility of causing this effect is that the infrared resonance wave of the specific wavelength can be well absorbed by the human body, and can drive the orderly distribution of sodium and potassium ions in the cell through the resonance fluctuation, and the original ion entropy increase is changed to a specific frequency resonance, so that the sodium and potassium ions move faster, and the existing commonly used far-infrared technology focuses on increasing the movement frequency of potassium and sodium ions through thermal effects, but the increase in movement frequency will cause the situation of disordered movement of potassium and sodium ions when passing through the cell channel, resulting in congestion, which is easy to cause secondary problems. Therefore, the biochip of the present invention makes the movement speed of sodium and potassium ions faster, rather than the ion movement frequency caused by the thermal effect is higher, so that potassium and sodium ions can pass quickly when passing through the cell channel, effectively avoiding congestion, thereby better and more efficiently promoting the depolarization of cell membrane potential, restoring cell function, inhibiting cell apoptosis and promoting cell regeneration, and the infrared resonance wave of variable frequency is not easy to have tolerance problems when treating the human body, so that there will be no rebound symptoms after stopping the far-infrared treatment, effectively ensuring the treatment effect, and the far-infrared of variable frequency will not produce obvious thermal effects after being absorbed by the human body.

[0168] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A bionic infrared biochip for enhancing cell activity, characterized in that: The biochip comprises a shell and a chip body encapsulated in the shell; The chip body comprises an inductive transceiver and a resonant crystal, wherein the inductive transceiver is electrically connected to the resonant crystal; The inductive transceiver is used to receive the biological waves emitted by the organism and / or the environment to the resonant crystal, and the resonant crystal is used to receive the biological waves transmitted from the inductive transceiver, resonate and amplify the received biological waves to form infrared resonant waves with a wavelength of 9.322µm~9.358µm, and transmit the infrared resonant waves to the inductive transceiver, and the inductive transceiver receives the infrared resonant waves transmitted from the resonant crystal and emits the infrared resonant waves; the infrared resonant waves are sinusoidal waves; The infrared resonance wave is a forward and reverse direction wave, and the forward and reverse switching frequency of the forward and reverse direction waves is 120MHz~130MHz.

2. The biochip according to claim 1, characterized in that: A plurality of chip bodies are provided, and each chip body array is arranged in the shell.

3. A method for using a bionic infrared biochip for enhancing cell activity, characterized in that: The steps include: Wearing or attaching the biochip according to any one of claims 1 to 2 on a living body, with the biochip being 0 to 30 cm away from the skin of the living body; The inductive transceiver receives the bio-waves emitted by the organism and / or the environment to the resonant crystal; The resonant crystal receives the bio-wave transmitted from the inductive transceiver, and forms an infrared resonant wave with a wavelength of 9.322µm~9.358 after resonant amplification of the received bio-wave, and the infrared resonant wave is a forward and reverse direction wave, and the forward and reverse switching frequency of the forward and reverse direction wave is 120MHz~130MHz, and transmits the infrared resonant wave to the inductive transceiver; The inductive transceiver receives the infrared resonance wave transmitted from the resonance crystal, and emits the infrared resonance wave to the biological body.

Images